Acceleron Announces Pricing of Public Offering of Common Stock
September 20 2017 - 8:31PM
Business Wire
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical
company in the discovery and development of TGF-beta therapeutics
intended to treat serious and rare hematologic, neuromuscular, and
pulmonary diseases, today announced that it has priced an
underwritten public offering of 5,405,406 shares of common stock at
a price to the public of $37.00 per share for gross proceeds of
$200.0 million. In connection with this offering, Acceleron has
granted the underwriters a 30-day option to purchase up to an
additional 810,810 shares of common stock.
J.P. Morgan Securities LLC, Citigroup and Leerink Partners LLC
are acting as joint book-running managers for the offering. The
offering is expected to close on or about September 25, 2017,
subject to the satisfaction of customary closing conditions.
Acceleron expects to receive net proceeds from the offering,
after deducting underwriting discounts and commissions and other
offering expenses payable by the company, of approximately $187.6
million. Acceleron intends to use the net proceeds from the
offering to conduct clinical trials and associated activities with
therapeutic candidates from its existing research pipeline and for
general and administrative expenses (including personnel-related
costs), capital expenditures and working capital and other general
corporate purposes, including potential acquisitions of rights to
additional programs from third parties.
The shares are being offered by Acceleron pursuant to an
effective shelf registration statement on Form S-3 that was
previously filed with the Securities and Exchange Commission (the
“SEC”). A preliminary prospectus supplement relating to and
describing the terms of the offering was filed with the SEC on
September 19, 2017. The final prospectus supplement relating to the
offering will be filed with the SEC. When available, copies of the
final prospectus supplement and the accompanying prospectus can be
obtained at the SEC’s website http://www.sec.gov or from J.P.
Morgan Securities LLC, Attention: Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, telephone:
1-866-803-9204 or email: prospectus-eq_fi@jpmchase.com; Citigroup
Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717 or telephone: 1-800-831-9146; and
Leerink Partners LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA, 02110, or by e-mail at
Syndicate@Leerink.com, or by phone at 800-808-7525, ext. 6132.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities in the offering, nor
shall there be any sale of these securities in any jurisdiction in
which an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such
jurisdiction.
About Acceleron
Acceleron is a leading biopharmaceutical company in the
discovery and development of TGF-beta therapeutics to treat serious
and rare hematologic, neuromuscular, and pulmonary diseases. Its
pioneering research and protein engineering platform engages the
target-rich TGF-beta superfamily and its remarkable ability to
regulate cellular growth and repair.
Under a global partnership with Celgene, Acceleron is in Phase 3
development with luspatercept, a potential first-in-class chronic
anemia therapy for the treatment of rare blood diseases. The
Company is also advancing a neuromuscular franchise with two
distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary
program with a Phase 2 trial of sotatercept planned in pulmonary
arterial hypertension. Acceleron has ongoing preclinical research
efforts targeting additional indications in these three disease
areas where there is significant unmet medical need.
Cautionary Note on Forward-Looking Statements
Certain statements contained in this release, including those
relating to the use of proceeds from the sale of common stock and
the expected closing of the offering, are forward-looking
statements that involve a number of risks and uncertainties that
could cause actual results to differ materially from those in the
forward-looking statements. These risks and uncertainties include,
but are not limited to, risks and uncertainties associated with the
consummation of the proposed offering and general economic
conditions and other risks identified from time to time in the
reports we file with the SEC, including our Annual Report on Form
10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form
8-K, which are available at www.sec.gov. We caution investors not
to place considerable reliance on the forward-looking statements
contained in this press release. The forward-looking statements in
this press release speak only as of the date of this document, and
we undertake no obligation to update or revise any of the
statements. Our business is subject to substantial risks and
uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170920006406/en/
Investors:Acceleron PharmaTodd James, 617-649-9393Vice
President, Investor Relations and Corporate
CommunicationsorMedia:BMC CommunicationsBrad Miles,
917-570-7340Bmiles@bmccommunications.com
Acceleron Pharma (NASDAQ:XLRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acceleron Pharma (NASDAQ:XLRN)
Historical Stock Chart
From Apr 2023 to Apr 2024